舒更葡糖与新斯的明对术后呼吸并发症及高级医疗利用的影响:多中心回顾性队列研究
该多中心回顾性队列研究纳入2016年1月至2021年6月两家学术医疗网络中接受全麻并使用舒更葡糖或新斯的明拮抗的成人手术患者,比较两种拮抗药与术后呼吸并发症及高级医疗利用的关系。结果显示,舒更葡糖与新斯的明在术后呼吸并发症(校正OR 1.01,95%CI 0.94-1.08;P=0.76)和高级医疗利用(校正OR 0.95,95%CI 0.89-1.01;P=0.11)方面无显著差异,等效性检验支持两者效果等效,且新斯的明在两项结局上非劣于舒更葡糖。
要点
- 舒更葡糖与新斯的明在术后呼吸并发症风险上无显著差异。
- 两种拮抗药在高级医疗利用复合结局上也无显著差异。
- 等效性检验支持舒更葡糖与新斯的明对上述结局效果等效。
核心结论
- 与新斯的明相比,使用舒更葡糖拮抗神经肌肉阻滞未降低术后呼吸并发症或术后高级医疗利用。
研究设计与样本
- 多中心回顾性队列研究,纳入两家学术医疗网络2016年1月至2021年6月接受全麻并接受舒更葡糖或新斯的明拮抗的成人手术患者,共83250例。
主要发现
- 5746例(6.9%)发生术后呼吸并发症,与拮抗药选择无关(校正OR 1.01,95%CI 0.94-1.08;P=0.76)。
- 排除来自专业护理机构的患者后,8372例(10.5%)需要高级医疗利用,与拮抗药选择无关(校正OR 0.95,95%CI 0.89-1.01;P=0.11)。
- 等效性检验支持舒更葡糖与新斯的明对两项结局效果等效,且新斯的明在术后呼吸并发症或高级医疗利用方面非劣于舒更葡糖。
- 拮抗药与主要不良心血管事件无关(校正OR 1.07,95%CI 0.94-1.21;P=0.32)。
临床怎么用
- 在选择神经肌肉阻滞拮抗药时,舒更葡糖并未显示出相较于新斯的明在降低术后呼吸并发症或高级医疗利用方面的优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reversing neuromuscular blockade with sugammadex can eliminate residual paralysis, which has been associated with postoperative respiratory complications. There are equivocal data on whether sugammadex reduces these when compared with neostigmine. We investigated the association of the choice of reversal drug with postoperative respiratory complications and advanced healthcare utilisation. We included adult patients who underwent surgery and received general anaesthesia with sugammadex or neostigmine reversal at two academic healthcare networks between January 2016 and June 2021. The primary outcome was postoperative respiratory complications, defined as post-extubation oxygen saturation < 90%, respiratory failure requiring non-invasive ventilation, or tracheal re-intubation within 7 days. Our main secondary outcome was advanced healthcare utilisation, a composite outcome including: 7-day unplanned intensive care unit admission; 30-day hospital readmission; or non-home discharge. In total, 5746 (6.9%) of 83,250 included patients experienced postoperative respiratory complications. This was not associated with the reversal drug (adjusted OR (95%CI) 1.01 (0.94-1.08); p = 0.76). After excluding patients admitted from skilled nursing facilities, 8372 (10.5%) patients required advanced healthcare utilisation, which was not associated with the choice of reversal (adjusted OR (95%CI) 0.95 (0.89-1.01); p = 0.11). Equivalence testing supported an equivalent effect size of sugammadex and neostigmine on both outcomes, and neostigmine was non-inferior to sugammadex with regard to postoperative respiratory complications or advanced healthcare utilisation. Finally, there was no association between the reversal drug and major adverse cardiovascular events (adjusted OR 1.07 (0.94-1.21); p = 0.32). Compared with neostigmine, reversal of neuromuscular blockade with sugammadex was not associated with a reduction in postoperative respiratory complications or post-procedural advanced healthcare utilisation.
引用
- Suleiman A, Munoz-Acuna R, Azimaraghi O, et al. The effects of sugammadex vs. neostigmine on postoperative respiratory complications and advanced healthcare utilisation: a multicentre retrospective cohort study. Anaesthesia. 2022. PMID: 36562202. doi:10.1111/anae.15940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。